A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (monofer) compared with oral iron for treatment of anemia in ibd (proceed)

American Journal of Gastroenterology

Volumn 108, Issue 12, 2013, Pages 1877-1888

  Reinisch, Walter ^a   Staun, Michael ^b   Tandon, Rakesh K ^c   Altorjay, Istvan ^d   Thillainayagam, Andrew V ^e   Gratzer, Cornelia ^a   Nijhawan, Sandeep ^f   Thomsen, Lars L ^g  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Pushpawati Singhania Research Institute   (India)

^d UNIVERSITY OF DEBRECEN   (Hungary)

^e IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^f SMS MEDICAL COLLEGE   (India)

^g Pharmacosmos AS   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; FERRO DURETTER; FERROUS SULFATE; HEMOGLOBIN; IRON DERIVATIVE; IRON ISOMALTOSIDE 1000; MESALAZINE; MONOFER; PREDNISOLONE; TRANSFERRIN; UNCLASSIFIED DRUG;

ADULT; ANAPHYLACTIC SHOCK; ANXIETY DISORDER; ARTICLE; CHEST TIGHTNESS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CROHN DISEASE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPNEA; ENTERITIS; ERYTHEMA; EUROPE; FEMALE; FLUSHING; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOTENSION; INDIA; INTERNET; IRON DEFICIENCY ANEMIA; IRON THERAPY; LOW VISION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ONLINE SYSTEM; OPEN STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; RESPIRATORY DISTRESS; SIDE EFFECT; TRANSFERRIN BLOOD LEVEL; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ADULT; ANEMIA, IRON-DEFICIENCY; DISACCHARIDES; FEMALE; FERRIC COMPOUNDS; HUMANS; INFLAMMATORY BOWEL DISEASES; INJECTIONS, INTRAVENOUS; IRON; MALE; PROSPECTIVE STUDIES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84889690772     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2013.335     Document Type: Article

References (39)

1. Wells CW, Lewis S, Barton JR et al. effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis 2006; 12 : 123-30.
2. Schreiber S, Wedel S. Diagnosis and treatment of anemia in inflammatory bowel disease. Inflamm Bowel Dis 1997; 3 : 204-16.
3. Gasche C.complications of inflammatory bowel disease. Hepatogastroenterology 2000; 47 : 49-56.
4. Gasche C, Lomer MC, Cavill I et al. Iron, anaemia, and inflammatory bowel diseases. Gut 2004; 53 : 1190-7.
5. Iron deficiency anaemia. The challenge. http://www.who.int/nutrition/ topics/ida/en/index.html.
6. Wilson A, Reyes E, Ofman J. Prevalence and outcomes of anemia in inflammatory bowel disease: A systematic review of the literature. Am J Med 2004; 116 (Suppl 7A) : 44S-9S.
7. Bodemar G, Kechagias S, Almer S et al. Treatment of anaemia in inflammatory bowel disease with iron sucrose. Scand J Gastroenterol 2004; 39 : 454-8.
8. Schroder O, Mickisch O, Seidler U et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease - a randomized, controlled, open-label, multicenter study. Am J Gastroenterol 2005; 100 : 2503-9.
9. Mamula P, Piccoli DA, Peck SN et al. Total dose intravenous infusion of iron dextran for iron-defi ciency anemia in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2002; 34 : 286-90.
10. Pizzi LT, Weston CM, Goldfarb NI et al. Impact of chronic conditions on quality of life in patients with inflammatory bowel disease. Inflamm Bowel Dis 2006; 12 : 47-52.
11. Reinisch W, Staun M, Bhandari S et al. State of the iron: How to diagnose and effi ciently treat iron deficiency anemia in inflammatory bowel disease. J Crohns Colitis 2013; 7 : 429-40.
12. Kulnigg S, Gasche C. Systematic review: Managing anaemia in Crohn's disease. Aliment Pharmacol ther 2006; 24 : 1507-23.
13. Gasche C, Berstad A, Befrits R et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 2007; 13 : 1545-53.
14. Lindgren S, Wikman O, Befrits R et al. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: A randomized, controlled, evaluator-blind, multicentre study. Scand J Gastroenterol 2009; 44 : 838-45.
15. Kulnigg S, Teischinger L, Dejaco C et al. Rapid recurrence of IBDassociated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment. Am J Gastroenterol 2009; 104 : 1460-7.
16. Locatelli F, Aljama P, Barany P et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19 (Suppl 2) : Ii1-47.
17. Gisbert JP, Bermejo F, Pajares R et al. Oral and intravenous iron treatment in inflammatory bowel disease: Hematological response and quality of life improvement. Inflamm Bowel Dis 2009; 15 : 1485-91.
18. FDA Advisory Committee Briefi ng Document, Drug Safety and Risk Management Committee, Division of Medical Imaging and Hematology Products and Offi ce of Oncology Drug Products and Offi ce of New Drugs, New Drug Application (NDA) 22-054 for Injectafer (Ferric Carboxymaltose) for the treatment of iron deficiency anemia in patients with heavy uterine bleeding or postpartum patients. 2008.
19. Sato K, Nohtomi K, Demura H et al. Saccharated ferric oxide (SFO)- induced osteomalacia: In vitro inhibition by SFO of bone formation and 1,25-dihydroxy-vitamin D production in renal tubules. Bone 1997; 21 : 57-64.
20. Sato K, Shiraki M. Saccharated ferric oxide-induced osteomalacia in Japan: Iron-induced osteopathy due to nephropathy. Endocr J 1998; 45 : 431-9.
21. Schouten BJ, Hunt PJ, Livesey JH et al. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: A prospective study. J Clin Endocrinol Metab 2009; 94 : 2332-7.
22. Schouten BJ, Doogue MP, Soule SG et al. Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia. Ann Clin Biochem 2009; 46 : 167-9.
23. Okada M, Imamura K, Iida M et al. Hypophosphatemia induced by intravenous administration of saccharated iron oxide. Klin Wochenschr 1983; 61 : 99-102.
24. Van Wyck DB, Mangione A, Morrison J et al. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: A randomized, controlled trial. Transfusion 2009; 49 : 2719-28.
25. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980; 1 : 514.
26. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317 : 1625-9.
27. Ganzoni AM. Intravenous iron-dextran: Therapeutic and experimental possibilities. Schweiz Med Wochenschr 1970; 100 : 301-3.
28. Ferro Duretter, Produktresume, 29 February 2012.
29. Guyatt G, Mitchell A, Irvine EJ et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989; 96 : 804-10.
30. Kulnigg S, Stoinov S, Simanenkov V et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: The ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastro enterol 2008; 103 : 1182-92.
31. Evstatiev R, Marteau P, Iqbal T et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 2011; 141 : 846-53.
32. Jahn MR, Andreasen HB, Futterer S et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer ®), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm 2011; 78 : 480-91.
33. Worldwide prevalence of anaemia 1993-2005, WHO global database on anaemia, World Health Organization, Center for Disease Control and Prevention, Atlanta 2008.
34. Werner T, Wagner SJ, Martinez I et al. Depletion of luminal iron alters the gut microbiota and prevents Crohn's disease-like ileitis. Gut 2011; 60 : 325-33.
35. Macdougall IC. Strategies for iron supplementation: Oral versus intravenous . Kidney Int Suppl 1999; 69 : S61-6.
36. Johnson DW, Herzig KA, Gissane R et al. A prospective crossover trial comparing intermittent intravenous and continuous oral iron supplements in peritoneal dialysis patients. Nephrol Dial Transplant 2001; 16 : 1879-84.
37. Low molecular weight iron dextran (Cosmofer ®) summary of product characteristics, dated 27 January 2010.
38. Szebeni J.complement activation-related pseudoallergy: A new class of drug-induced acute immune toxicity. Toxicology 2005; 216 : 106-21.
39. Australian Public Assessment Report for Ferric Carboxymaltose, TGA Health Safety Regulation, May 2011.